DepoMed Inc. (NASDAQ: DEPO), a specialty pharmaceutical company engaged in the development and commercialization of differentiated products, earlier this week announced that its GRALISE™ tablets are now available as a once-daily treatment for postherpetic neuralgia.
Jim Schoeneck, president and CEO of DepoMed, said earlier this week that the launch of GRALISE is a major milestone for the company. He added that the company also received positive reactions from insurers and expects to have broad managed care coverage.
Synergetics Inc. (NASDAQ: SURG), a medical device company, on Tuesday released its fourth-quarter financial results. The company reported fourth-quarter net income of $2 million, representing an increase of 100% over the same period in the previous year. The company’s fourth-quarter sales jumped 21% on a year-over-year basis to $13.1 million.
Dave Hable, president and CEO of Synergetics, said that the company’s record results for the fourth quarter highlight the solid progress it has made since last year in building its sales of ophthalmic and neurosurgical products and in improving its profitability.
Dynavax Technologies Corp. (NASDAQ: DVAX), a biopharmaceutical company engaged in the discovery and development of products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases, earlier this week reported that tests showed its hepatitis B vaccine worked better on hard-to-treat patients than an older vaccine.
Additional articles published by Beacon Equity Research can be found on their website at www.BeaconEquity.com
Let us hear your thoughts below: